Casdin Partners Master Fund, L Buys 275,000 Shares of Standard BioTools (NASDAQ:LAB) Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L purchased 275,000 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were acquired at an average cost of $1.17 per share, with a total value of $321,750.00. Following the completion of the transaction, the director owned 61,375,000 shares in the company, valued at $71,808,750. This trade represents a 0.45% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Wednesday, November 12th, Casdin Partners Master Fund, L acquired 375,000 shares of Standard BioTools stock. The stock was acquired at an average price of $1.19 per share, for a total transaction of $446,250.00.
• On Tuesday, November 11th, Casdin Partners Master Fund, L bought 300,000 shares of Standard BioTools stock. The shares were acquired at an average price of $1.20 per share, with a total value of $360,000.00.
• On Friday, November 7th, Casdin Partners Master Fund, L purchased 225,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.12 per share, for a total transaction of $252,000.00.
• On Tuesday, September 9th, Casdin Partners Master Fund, L purchased 100,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.29 per share, for a total transaction of $129,000.00.
• On Wednesday, September 3rd, Casdin Partners Master Fund, L acquired 250,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.27 per share, with a total value of $317,500.00.
• On Tuesday, August 26th, Casdin Partners Master Fund, L bought 125,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.26 per share, for a total transaction of $157,500.00.
• On Monday, August 25th, Casdin Partners Master Fund, L purchased 200,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.24 per share, with a total value of $248,000.00.
• On Friday, August 22nd, Casdin Partners Master Fund, L purchased 200,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.26 per share, with a total value of $252,000.00.
• On Friday, August 15th, Casdin Partners Master Fund, L acquired 150,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.22 per share, for a total transaction of $183,000.00.
• On Thursday, August 14th, Casdin Partners Master Fund, L acquired 133,220 shares of Standard BioTools stock. The shares were purchased at an average price of $1.21 per share, with a total value of $161,196.20.

Standard BioTools Stock Performance

Shares of Standard BioTools stock opened at $1.20 on Friday. The company has a 50-day simple moving average of $1.29 and a two-hundred day simple moving average of $1.23. The stock has a market capitalization of $461.48 million, a PE ratio of -3.75 and a beta of 1.25. Standard BioTools Inc. has a 52-week low of $0.92 and a 52-week high of $2.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of LAB. Long Focus Capital Management LLC bought a new stake in shares of Standard BioTools during the 1st quarter valued at about $7,236,000. Pacific Capital Partners Ltd bought a new stake in Standard BioTools during the first quarter valued at approximately $1,701,000. Kent Lake PR LLC purchased a new stake in Standard BioTools during the second quarter valued at approximately $1,200,000. Nuveen LLC purchased a new position in shares of Standard BioTools during the 1st quarter worth $862,000. Finally, Royce & Associates LP grew its position in shares of Standard BioTools by 37.4% during the 1st quarter. Royce & Associates LP now owns 2,000,503 shares of the company’s stock valued at $2,161,000 after acquiring an additional 545,000 shares during the period. 53.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on LAB shares. TD Cowen cut their target price on Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a research note on Wednesday, November 5th. Cowen downgraded Standard BioTools from a “buy” rating to a “hold” rating in a report on Wednesday, August 13th. Wall Street Zen downgraded Standard BioTools from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Standard BioTools in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $1.35.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.